Research graph
References from Unraveling the ameliorative effects of Ling-Gui-Zhu-Gan decoction on MASLD: an integrative gut microbiota and lipidomic study. Local targets link to admitted publications; unresolved targets remain external evidence.
Glycyrrhizin: an alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
10.1016/j.pharmthera.2020.107618 · 2020 · External reference
Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages
10.1186/s13020-021-00559-3 · 2022 · External reference
The traditional Chinese formulae Ling-Gui-Zhu-Gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules
10.1186/s12906-018-2424-1 · 2019 · External reference
Glycyrrhetinic acid regulates impaired macrophage autophagic flux in the treatment of non-alcoholic fatty liver disease
10.3389/fimmu.2022.959495 · 2022 · External reference
Alterations in gut microbiota improve SCFA production and fiber utilization in Tibetan pigs fed alfalfa diet
10.3389/fmicb.2022.969524 · 2022 · External reference
review of the studies on food-derived factors which regulate energy metabolism via the modulation of lipid-sensing nuclear receptors
10.1080/09168451.2018.1559025 · 2019 · External reference
Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
10.3389/fphar.2022.1007274 · 2022 · External reference
Phosphatidylserine in the brain: metabolism and function
10.1016/j.plipres.2014.06.002 · 2014 · External reference
Pathophysiological mechanisms underlying MAFLD
10.1016/j.dsx.2020.09.026 · 2020 · External reference
Natural products in licorice for the therapy of liver diseases: progress and future opportunities
10.1016/j.phrs.2019.04.025 · 2019 · External reference
Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway
10.1016/j.phymed.2023.155285 · 2024 · External reference
Unresolved reference
2017 · External reference
PNPLA3 rs139051 is associated with phospholipid metabolite profile and hepatic inflammation in nonalcoholic fatty liver disease
10.12998/wjcc.v6.i10.355 · 2018 · External reference
Abnormal differentiation of intestinal epithelium and intestinal barrier dysfunction in diabetic mice associated with depressed Notch/NICD transduction in Notch/Hes1 signal pathway
10.1002/cbin.10323 · 2014 · External reference
Lingguizhugan decoction targets intestinal microbiota and metabolites to reduce insulin resistance in high-fat diet rats
10.2147/dmso.s370492 · 2022 · External reference
TLCD1 and TLCD2 regulate cellular phosphatidylethanolamine composition and promote the progression of non-alcoholic steatohepatitis
10.1038/s41467-022-33735-6 · 2022 · External reference
Multi-omics joint analysis: pachymic acid ameliorated non-alcoholic fatty liver disease by regulating gut microbiota
10.1016/j.foodres.2025.116178 · 2025 · External reference
Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation
10.1007/s12072-025-10953-w · 2026 · External reference
Mass spectrometry-based lipidomics in food science and nutritional health: a comprehensive review
10.1111/1541-4337.12603 · 2020 · External reference
Lingguizhugan oral solution alleviates MASLD by regulating bile acids metabolism and the gut microbiota through activating FXR/TGR5 signaling pathways
10.3389/fphar.2024.1426049 · 2024 · External reference
Vitamin K2 alleviates metabolic dysfunction-associated steatotic liver disease through mitochondrial dysfunction modulation via gut microbiota
10.31083/ijvnr37275 · 2025 · External reference
LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver
10.1016/j.hbpd.2021.05.008 · 2021 · External reference
Unresolved reference
2023 · External reference
Linggui Zhugan Formula improves glucose and lipid levels and alters gut microbiota in high-fat diet-induced diabetic mice
10.3389/fphys.2019.00918 · 2019 · External reference
Ling-Gui-Zhu-Gan decoction improves hepatic steatosis through ALKBH1-mediated DNA N6-methyladenosine modification
10.1016/j.jep.2025.120893 · 2026 · External reference
Brief introduction of an international expert consensus statement: a new definition of metabolic associated fatty liver disease
10.3969/j.issn.1672-5069.2020.03.039 · 2020 · External reference
Lingguizhugan decoction protects against high-fat-diet-induced nonalcoholic fatty liver disease by alleviating oxidative stress and activating cholesterol secretion
10.1155/2017/2790864 · 2017 · External reference
Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula
10.1016/j.syapm.2012.12.009 · 2013 · External reference
Sanren decoction ameliorates metabolic dysfunction-associated steatotic liver disease by protecting mitochondrial function
10.1007/s11655-025-3845-6 · 2026 · External reference
Protective effects of glycycoumarin on liver diseases
10.1002/ptr.6598 · 2020 · External reference
Erchen decoction and linguizhugan decoction ameliorate hepatic insulin resistance by inhibiting IRS-1Ser307 phosphorylation in vivo and in vitro
10.1155/2017/1589871 · 2017 · External reference
Unresolved reference
1994 · External reference
Betulinic acid prevents liver fibrosis by binding Lck and suppressing Lck in HSC activation and proliferation
10.1016/j.jep.2022.115459 · 2022 · External reference
Lingguizhugan decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: a whole trancriptome study by RNA-Seq
10.18632/oncotarget.19734 · 2017 · External reference
